Experimental therapy in myelofibrosis with myeloid metaplasia

Myelofibrosis with myeloid metaplasia (MMM) is a Philadelphia chromosome-negative myeloproliferative disorder that is characterised by constitutional symptoms, progressive anaemia and extramedullary haematopoiesis. There are no curative therapies available for patients with MMM apart from stem cell transplantation, which is associated with significant morbidity and mortality, and for which most patients are not suitable candidates. Traditional pharmacological therapy of MMM has focused on the palliation of symptoms associated with myeloproliferation and correction of cytopoenias. Recently, new findings regarding the molecular basis of MMM and the pathogenesis of the associated bone marrow stromal reaction have provided both basic and clinical researchers with invaluable tools to develop effective targeted therapies for patients with MMM. Several novel treatment strategies are being investigated including antiangiogenic agents, signal transduction inhibitors, inhibitors of fibrogenesis and small-molecule inhibitors of the JAK2V617F mutation. This article reviews the current status of experimental novel therapies for MMM.

[1]  D. Rondelli.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2008, Haematologica.

[2]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[3]  H. Kantarjian,et al.  Lenalidomide therapy in myelofibrosis with myeloid metaplasia. , 2006, Blood.

[4]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[5]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[6]  R. Mesa,et al.  Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis , 2006, Cancer.

[7]  R. Schiffelers,et al.  ICS-283: a system for targeted intravenous delivery of siRNA , 2006, Expert opinion on drug delivery.

[8]  N. Donato,et al.  The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway , 2006 .

[9]  N. Donato,et al.  Degradation of c-Myc by WP1130 Through Activation of a Novel Proteasomal-Dependent Pathway , 2006 .

[10]  R. Mesa,et al.  Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2V617F and response to erythropoietin therapy , 2006, Cancer.

[11]  L. Bañez,et al.  VEGF inhibitors in cancer therapy. , 2006, Current pharmaceutical design.

[12]  A. Kelso,et al.  Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. , 2006, Cancer research.

[13]  G. Barosi,et al.  Glivec/STI571 Treatment Stimulates Megakaryopoiesis and Normalizes PDGF Receptor beta Kinase Expression in Thrombocytopenic Patients with Myeloid Metaplasia with Myelofibrosis. , 2005 .

[14]  W. Vainchenker,et al.  Proteasome Inhibitor Bortezomib Can Inhibit Bone Marrow Fibrosis Development in a Murine Model of Myelofibrosis. , 2005 .

[15]  B. Cheson,et al.  A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL). , 2005 .

[16]  D. Steensma,et al.  The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .

[17]  A. Tefferi,et al.  Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia , 2005, Cancer.

[18]  J. Reilly,et al.  Der(6)t(1;6)(q21–23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia , 2005, British journal of haematology.

[19]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[20]  J. Issa,et al.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Hoffman,et al.  Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. , 2005, Blood.

[22]  H. Koeffler,et al.  Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. , 2005, Leukemia research.

[23]  A. Pancrazzi,et al.  A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. , 2005, Blood.

[24]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[25]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[26]  W. Vainchenker,et al.  Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. , 2005, Cancer research.

[27]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[28]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[29]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[30]  A. Dalgleish,et al.  Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. , 2005, Microvascular research.

[31]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[32]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[33]  R. Mesa,et al.  A Phase 2 Consortium (P2C) Trial of R115777 (Tipifarnib) in Myelofibrosis with Myeloid Metaplasia. , 2004 .

[34]  M. Weller,et al.  SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.

[35]  J. S. Sawyer.  Synthesis and Activity of New Aryl‐ and Heteroaryl‐Substituted 5,6‐Dihydro‐4H‐pyrrolo[1,2‐b]pyrazole Inhibitors of the Transforming Growth Factor‐β Type I Receptor Kinase Domain. , 2004 .

[36]  J. Dupont,et al.  Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. , 2004, Clinical colorectal cancer.

[37]  The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Dalgleish,et al.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Françoise Gellibert,et al.  Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. , 2004, Journal of medicinal chemistry.

[40]  R. Mesa,et al.  Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. , 2004, Mayo Clinic proceedings.

[41]  M. Griesshammer,et al.  Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. , 2004, Blood.

[42]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[43]  W. Vainchenker,et al.  Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. , 2004, Experimental hematology.

[44]  E. Ralfkiær,et al.  Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis , 2003, American journal of hematology.

[45]  H. Hasselbalch.  SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis. , 2003, Medical hypotheses.

[46]  Z. Estrov,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. , 2003, Blood.

[47]  G. Wolbring,et al.  Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs , 2003, Journal of Pharmacology and Experimental Therapeutics.

[48]  H. Kantarjian,et al.  Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders , 2003, Cancer.

[49]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[50]  M. Martyré.  Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. , 2003, Current hematology reports.

[51]  H. Kantarjian,et al.  Phase II study of SU5416—a small‐molecule, vascular endothelial growth factor tyrosine‐kinase receptor inhibitor—in patients with refractory myeloproliferative diseases , 2003, Cancer.

[52]  A. Tefferi,et al.  Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. , 2003, Blood.

[53]  R. Kurzrock,et al.  Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. , 2003, Blood.

[54]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  W. Vainchenker,et al.  Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. , 2002, Blood.

[56]  A. Migliaccio,et al.  Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). , 2002, Blood.

[57]  D. Steensma,et al.  Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. , 2002, Blood.

[58]  Jen-Chin Wang,et al.  Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation , 2002, British journal of haematology.

[59]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[60]  Ruth Lehr,et al.  Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). , 2002, Journal of medicinal chemistry.

[61]  O. Haas,et al.  Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. , 2002, Blood.

[62]  W. Vainchenker,et al.  Prominent role of TGF-1 in thrombopoietin-induced myelofibrosis in mice , 2002 .

[63]  S. Margolin,et al.  A phase II trial of pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone), a novel anti‐fibrosing agent, in myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.

[64]  R. Mesa,et al.  Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.

[65]  N. Kinukawa,et al.  Primary Chronic Myelofibrosis: Clinical and Prognostic Evaluation in 336 Japanese Patients , 2001, International journal of hematology.

[66]  W. R. Bishop,et al.  Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules* , 2000, The Journal of Biological Chemistry.

[67]  F. Wendling,et al.  Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. , 2000, Blood.

[68]  P. Rameshwar,et al.  NF-κB as a Central Mediator in the Induction of TGF-β in Monocytes from Patients with Idiopathic Myelofibrosis: An Inflammatory Response Beyond the Realm of Homeostasis1 , 2000, The Journal of Immunology.

[69]  A. Tefferi.  Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[70]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[71]  Gilla Kaplan,et al.  Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production , 1999 .

[72]  R. Kurzrock,et al.  RAS and leukemia: from basic mechanisms to gene-directed therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  G. Prendergast,et al.  Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.

[74]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[75]  W. Vainchenker,et al.  High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. , 1997, Blood.

[76]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[77]  J. Esteve,et al.  Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosis , 1997, British journal of haematology.

[78]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.

[79]  A. Levitzki,et al.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.

[80]  J. Reilly,et al.  Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis , 1994, British journal of haematology.

[81]  Arturo Pereira,et al.  Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. , 1991, Acta haematologica.

[82]  P. Fialkow,et al.  Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. , 1978, Blood.